Market Cap | 4.97M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -3.82M | Forward P/E | -1.03 | EPS next Y | - | 50D Avg Chg | 32.00% |
Sales | 827.41k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 21.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -50.00% |
Recommedations | - | Quick Ratio | 0.15 | Shares Outstanding | 121.27M | 52W Low Chg | 86.00% |
Insider Own | 0.06% | ROA | -244.22% | Shares Float | 106.83M | Beta | 0.98 |
Inst Own | 11.84% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.04 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 203,546 | Target Price | - |
Oper. Margin | -1,039.88% | Earnings Date | Nov 11 | Volume | 19,784 | Change | -2.38% |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.